Crowley Maeve P, Eustace Joseph A, O'Shea Susan I, Gilligan Oonagh M
Clinical Research Facility, University College Cork, Cork, Ireland Department of Haematology, Cork University Hospital, Cork, Ireland
Clinical Research Facility, University College Cork, Cork, Ireland.
Clin Appl Thromb Hemost. 2014 Sep;20(6):600-6. doi: 10.1177/1076029614521280. Epub 2014 Jan 30.
Myeloma has a well-described association with venous thromboembolism (VTE). There are few dedicated studies investigating the incidence and risk factors. Many assessment scores have been suggested to estimate the risk of VTE in patients with cancer but these have been validated in solid organ tumors. The records of patients with myeloma attending a university hospital between January 2007 and December 2012 were reviewed to investigate the incidence of VTE and the associated risk factors. In all, 217 patients with a mean (standard deviation) age at diagnosis of 65 (12) years were included. Of 217 patients, 12% had an episode of VTE, 69% received at least 1 immunomodulatory agent, and 95% had low or intermediate risk of VTE according to the Khorana score. Venous thromboembolism was a frequent occurrence in this cohort. Patients had many risk factors for VTE but no one was predictive. As myeloma outcomes continue to improve, a dedicated prospective study is warranted to investigate the most appropriate thromboprophylaxis strategy.
骨髓瘤与静脉血栓栓塞（VTE）之间的关联已得到充分描述。专门研究其发病率和危险因素的研究较少。已有许多评估评分用于估计癌症患者发生VTE的风险，但这些评分已在实体器官肿瘤中得到验证。回顾了2007年1月至2012年12月在一家大学医院就诊的骨髓瘤患者的记录，以调查VTE的发病率及相关危险因素。总共纳入了217例患者，诊断时的平均（标准差）年龄为65（12）岁。在217例患者中，12%发生过VTE事件，69%至少接受过1种免疫调节剂治疗，根据Khorana评分，95%的患者发生VTE的风险为低或中度。静脉血栓栓塞在该队列中很常见。患者有许多VTE的危险因素，但没有一个具有预测性。随着骨髓瘤治疗效果的不断改善，有必要开展一项专门的前瞻性研究来探讨最合适的血栓预防策略。
